Latest Breaking News On - Hartley atkinson - Page 9 : comparemela.com

Children s medicines quite challenging to develop: AFT Pharmaceutical CEO

Children s medicines quite challenging to develop: AFT Pharmaceutical CEO
stuff.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stuff.co.nz Daily Mail and Mail on Sunday newspapers.

United statesNew zealandHartley atkinsonDrug administrationMaxigesic oral liquidஒன்றுபட்டது மாநிலங்களில்புதியது ஜீலாந்துஹார்ட்லி அட்கின்சன்

The Monitor economy Q&A: Hartley Atkinson, AFT Pharmaceuticals CEO

Parts of the economy are doing well, but the Covid-19 vaccination rate leaves NZ vulnerable, says Hartley Atkinson.

New zealandSouth australiaHartley atkinsonபுதியது ஜீலாந்துதெற்கு ஆஸ்திரேலியாஹார்ட்லி அட்கின்சன்

Covid-free Australia would help AFT Pharmaceuticals growth

Sales grew from $105 million the previous year to $113m, compared with April guidance of $111m. Underlying operating profit of $10.7m was near the upper end of a downgraded forecast of between $9m and $11m. Excluding a one-off gain, operating profit in the previous year was $11.4m. The company expected operating profit this year between $18m and $23m. However, investors will have to wait for a dividend as AFT first wanted to reduce its net debt to between $25m and $30m. Net debt fell to $35.2m from $37.1m during the year. AFT signed a number of deals remotely during the year, which was challenge, Atkinson said.

United statesNew zealandHartley atkinsonUnited hikma pharmaceuticalsUnited kingdom based hikma pharmaceuticalsNorth americaஒன்றுபட்டது மாநிலங்களில்புதியது ஜீலாந்துஹார்ட்லி அட்கின்சன்வடக்கு அமெரிக்கா

AFT Pharmaceuticals reports $7 8m net profit

Local drugmaker AFT Pharmaceuticals has posted a lower full-year profit as the pandemic and disruptions to its supply chain affected sales. AFT Pharmaceuticals underlying profit for the year was $10.8m, in line with guidance given last month. Photo: 123RF The company reported a net profit of $7.8 million for the year ended March compared with a profit of $12.7m the year before, although that was inflated by a $9.8m one-off gain. AFT managing director Hartley Atkinson said the year had been challenging but the company had made progress in revenue and recognition of its key product, the Maxigesic painkiller range. We have delivered these improved financial results in the face of multiple supply disruptions, delays to product launches, to regulatory approvals and to manufacturing audits around the world.

New zealandUnited statesHartley atkinsonNorth americaபுதியது ஜீலாந்துஒன்றுபட்டது மாநிலங்களில்ஹார்ட்லி அட்கின்சன்வடக்கு அமெரிக்கா

Drug company s shares surge after deal signed in world s largest market

AFT Pharmaceuticals chief executive Hartley Atkinson says the US pharmaceutical market is key for the company, Shares in AFT Pharmaceuticals soared as much as 18 per cent after it signed its first distribution deal in the United States, the world s largest drug market. The Auckland-based company said on Wednesday it had signed an exclusive licensing and distribution deal with Hikma Pharmaceuticals for the commercialisation of its intravenous, opioid-free Maxigesic IV post-operative pain relief medicine in the US. Based in the United Kingdom, Hikma is the third-largest supplier of generic injectable medications by volume in the US. The deal gives AFT a foothold into a post-operative pain management medication market worth an estimated US$745 million (NZ$1 billion) in 2019, and expected to grow to US$1.7b (NZ$2.4b) by 2028. The company’s product offers an alternative to opioids in the US, where addiction to the drugs has become an epidemic.

New zealandUnited statesUnited kingdomHartley atkinsonDrug administrationHikma pharmaceuticalsபுதியது ஜீலாந்துஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்ஹார்ட்லி அட்கின்சன்ஹிக்மா மருந்துகள்